Geert Kleinnibbelink

Chapter 6 148 First author Study design Study population WHO group NYHA class PH specific therapy at inclusion Follow-up (y) Endpoint All-cause mortality Haeck et al. 15 Retrospective N: 142 Age: 59±15 Female sex: 63% 1 (n=53) 2 (n=46) 3 (n=32) 4 (n=7) 5 (n=4) NR Endothelin receptor antagonist (n=37) Phosphodiesterase-5 inhibitor (n=19) Β-blocker (n=44) Angiotensin-converting-enzyme inhi- bitor/ angiotensin II receptor antago- nist (n=58) Diuretics (n=91) Anticoagulation (n=64) 2.6y All-cause mortality van Kessel et al. 9 Retrospective N: 53 Age: 56±9 (n=25); 54±17 (n=28) Female sex: 66% Mixed (n=53) II (41.5%) III (41.5%) IV (9.4%) NR (7.%) Mono therapy (n=27) Double therapy (n=16) Triple therapy (n=8) 2.3y All-cause mortality Park et al. 10 Retrospective N: 51 Age: 48±14 Female sex: 78% 1 (n=51) I (4%) II (61%) III (35%) Phosphodiesterase-5 inhibitor (n=29 Endothelin receptor antagonist (n=26) Prostacyclins (n=32) Calcium channel blockers (n=9) 3.8y All-cause mortality Sachdev et al. 23 NR N: 80 Age: 56±14 Female sex: 76% 1 (n=80) I-II (28%) III (63%) IV (9%) Treatment naïve 2.0y All-cause mortality Vitarelli et al. 28 † NR N: 73 Age: 53±13 Female sex: 56% 1 (n=25) 2 (n=25) 4 (n=23) I-II (71%) III-IV (29%) NR 2.0y All-cause mortality Symbols denote † =3D strain analysis. (WHO=World Health Organisation; NYHA=New York Heart Association; PH=Pulmonary Hypertension; NR=Not Reported) Table 3. (Continued)